University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Hope Rugo

Hope Rugo, M.D.

Breast cancer specialist

Dr. Hope Rugo is a hematologist and oncologist specializing in breast cancer treatment. Rugo joined the UCSF Carol Franc Buck Breast Care Center after a decade at UCSF Medical Center working in the area of malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer.

Rugo, co-director of the Breast Oncology Clinical Trials Program, has a special interest in therapies for breast cancer and is the principal investigator of several clinical trials testing these treatments. She is a professor of medicine at UCSF and an investigator of SPORE (Specialized Program of Research Excellence in Breast Cancer) in the Bay Area.

Conditions & Treatments

Clinics

Cancer Risk Program
1600 Divisadero St., Second Floor
San Francisco, CA 94143-1714
Phone: (415) 885-7779
Fax: (415) 885-3787

Hours: Monday to Friday
9 a.m. – 5 p.m.

Carol Franc Buck Breast Care Center
1600 Divisadero St., Second Floor
San Francisco, CA 94115
Phone: (415) 353-7070
Fax: (415) 353-7050

Hours: Monday to Friday
8 a.m. – 5 p.m.

More about Hope Rugo

Additional Languages

French
Spanish

Education

University of Pennsylvania School of Medicine 1984

Residencies

UCSF Medical Center, Internal Medicine 1987

Fellowships

UCSF Medical Center, Hematology 1990
UCSF Medical Center, Oncology 1995

Selected Research and Publications

  1. McCann B, Miaskowski C, Koetters T, Baggott C, West C, Levine JD, Elboim C, Abrams G, Hamolsky D, Dunn L, Rugo H, Dodd M, Paul SM, Neuhaus J, Cooper B, Schmidt B, Langford D, Cataldo J, Aouizerat BE. Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. J Pain. 2012 May; 13(5):425-37.
  2. Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba SG. Antiemesis. J Natl Compr Canc Netw. 2012 Apr 1; 10(4):456-85.
  3. Rugo HS. Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning? J Clin Oncol. 2012 Mar 20; 30(9):898-901.
  4. Hurria A, Browner IS, Cohen HJ, Denlinger CS, Deshazo M, Extermann M, Ganti AK, Holland JC, Holmes HM, Karlekar MB, Keating NL, McKoy J, Medeiros BC, Mrozek E, O'Connor T, Petersdorf SH, Rugo HS, Silliman RA, Tew WP, Walter LC, Weir AB, Wildes T. Senior adult oncology. J Natl Compr Canc Netw. 2012 Feb 1; 10(2):162-209.
  5. Rugo HS. Neoadjuvant therapy for HER2-positive early-stage breast cancer: the future is almost here. Oncology (Williston Park). 2012 Jan; 26(1):26, 28-9.
  6. Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu S, Kerlikowske K, Ziv E. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat. 2012 Apr; 132(3):1107-18.
  7. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011 Dec 15; 25(24):2559-72.
  8. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9; 366(6):520-9.
  9. Rugo HS, O'Shaughnessy JA, Perez EA. Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now? Clin Adv Hematol Oncol. 2011 Nov; 9(11):1-16.
  10. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol. 2011 Nov 10; 29(32):4286-93.
  11. Lorizio W, Rugo H, Beattie MS, Tchu S, Melese T, Melisko M, Wu AH, Lawrence HJ, Nikoloff M, Ziv E. Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med. 2011; 3(10):64.
  12. Mayer EL, Baurain JF, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart-Cussac A. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res. 2011 Nov 1; 17(21):6897-904.
  13. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2796-801.
  14. Perez EA, Mooberry S, Twelves C, Rugo HS. New frontiers and treatment paradigms for metastatic breast cancer. Clin Adv Hematol Oncol. 2011 Aug; 9(8 Suppl 20):1-16.
  15. Rugo HS, Rosen MP. Reducing the long-term effects of chemotherapy in young women with early-stage breast cancer. JAMA. 2011 Jul 20; 306(3):312-4.
  16. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011 Jul 15; 17(14):4834-43.
  17. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun 7; 104(12):1828-35.
  18. Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol. 2011 Jun 20; 29(18):2459-65.
  19. Greenberg S, Stopeck A, Rugo HS. Systemic treatment of early breast cancer--a biological perspective. J Surg Oncol. 2011 May 1; 103(6):619-26.
  20. McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res. 2011 May 15; 17(10):3398-407.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2012 The Regents of The University of California